Journal of Molecular Structure, cilt.1347, 2025 (SCI-Expanded)
Using the pyrazine-modulated pentapyridyltetraamine ligand N2,N2′-(pyridine-2,6-diyl)bis(N6-(pyrazin-2-yl)pyridine-2,6-diamine) H4N9-2pz, three new mononuclear complexes [Cu(H4N9-2pz)](NO3)2∙(CH3CN) 1, [Cu(H4N9-2pz)]Cl2∙2(H2O) 2 and [Cu(H3N9-2pz)] (CH3COO)∙2.5(H2O) 3 have been synthesized, structurally characterized, and their bioactivity properties studied. In vitro analysis of complexes 1-3 revealed that they inhibited AChE and BChE more effectively than the widely available inhibitor tacrine (IC50: 123.58 ± 6.80 and 146.18 ± 7.91 µM). Additionally, their IC50 values for AChE and BChE ranged from 32.87 to 68.15 and 14.60 to 31.68 µM, respectively. The g|| and g┴ components of the g factor have similar values in the EPR spectrum of complexes 1-3 (g|| = 2.0179 and g┴ = 2.1246 for 1; g|| = 2.0044 and g┴ = 2.1425 for 2; g|| = 2.0118 and g┴ = 2.1356 for 3). The single crystal X-ray approach revealed a distorted trigonal bipyramidal geometry of the complexes, which is consistent with the "inverted type" of EPR spectra (g┴ > g||∼ ge), measured magnetic moment susceptibility, and electronic spectrum studies. The comparable structures of complexes 1–3 suggest that the H4N9-2pz ligand, rather than the nitrate, carboxylate, or chloride counterions, is critical for complex formation.